J.Molner submits second drug to Health Canada
Tallinn, 2023-03-28 08:31 CEST --
J. Molner has successfully presented its second submission to Health Canada. Molner’s generic injectable antiemetic drug, MOC-002, is expected to be approved in Q2-Q3, 2024.
For additional information please contact:
Management Board member
+372 536 00 346